AstraZeneca PLC
camizestrant
HR-positive, HER2-negative advanced breast cancer
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews camizestrant for HR-positive, HER2-negative advanced breast cancer around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 14h ago
“The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 i”